E
Elisa Nuti
Researcher at University of Pisa
Publications - 104
Citations - 2120
Elisa Nuti is an academic researcher from University of Pisa. The author has contributed to research in topics: Matrix metalloproteinase inhibitor & Matrix metalloproteinase. The author has an hindex of 27, co-authored 100 publications receiving 1742 citations. Previous affiliations of Elisa Nuti include University of Florence & Temple University.
Papers
More filters
Journal ArticleDOI
Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies.
Murat Bozdag,Marta Ferraroni,Elisa Nuti,Daniela Vullo,Armando Rossello,Fabrizio Carta,Andrea Scozzafava,Claudiu T. Supuran +7 more
TL;DR: A difference of one atom (N vs CH) in two isostructural sulfonamides leads to drastic differences of activity, phenomenon understood at the atomic level through the high resolution crystallographic structure and kinetic measurements reported in the paper.
Journal ArticleDOI
Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
TL;DR: Analysis of more recent results in this field reported on journals and patents will be developed, to consider some of the more interesting new highly selective synthetic MMPI, their SARs, the new theoretical approaches used for modelling and the results of their biological evaluations.
Journal ArticleDOI
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Armando Rossello,Elisa Nuti,Elisabetta Orlandini,Paolo Carelli,Simona Rapposelli,Marco Macchia,Filippo Minutolo,Laura Carbonaro,Adriana Albini,Roberto Benelli,Giovanni Cercignani,Gillian Murphy,Aldo Balsamo +12 more
TL;DR: The most potent derivative of this type, 10a, shows similar anti-invasive properties to the analogue reference drug CGS27023A, 2, in an in vitro model of invasion on matrigel, carried out on cellular lines of fibrosarcoma HT1080 (tumoural cells over-expressing M MP-2 and MMP-9).
Journal ArticleDOI
Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II
Takehiko Takayanagi,Steven J. Forrester,Tatsuo Kawai,Takashi Obama,Toshiyuki Tsuji,Katherine J. Elliott,Elisa Nuti,Armando Rossello,Hang Fai Kwok,Rosario Scalia,Victor Rizzo,Satoru Eguchi +11 more
TL;DR: Vascular ADAM17 mediates AngII-induced cardiovascular remodeling via epidermal growth factor receptor activation independent of blood pressure regulation, and seems to be a unique therapeutic target for the prevention of hypertensive complications.
Journal ArticleDOI
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tiziano Tuccinardi,Adriano Martinelli,Elisa Nuti,Paolo Carelli,Federica Balzano,Gloria Uccello-Barretta,Gillian Murphy,Armando Rossello +7 more
TL;DR: The hydroxamate (R)-b can be considered as a progenitor of a new class of biphenylsulfonamido-based inhibitors that differ from compound a in the presence of an alkyl side chain on the C alpha atom, and show different potency and selectivity profiles on the two MMPs considered.